JP Morgan Chase’s Meridian Bioscience Inc VIVO Stock Holding History

JP Morgan Chase’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300	Closed	-$6K	–	7151
2021 Q3	$6K	Buy	+300	New	+$5.98K	﹤0.01%	6239

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's VIVO Position: Q1 2023 in Review

JP Morgan Chase sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 381,880 shares — an estimated $12.7M sold.

JP Morgan Chase first reported a position in VIVO in Q2 2013 and held it in 33 quarters. The position peaked at $12.7M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

JP Morgan Chase reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
JP Morgan Chase sold 381,880 Meridian Bioscience Inc shares in Q1 2023, an estimated $12.7M.
JP Morgan Chase first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 33 quarters.
JP Morgan Chase's Meridian Bioscience Inc position peaked at $12.7M in Q4 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.